Biotechnology Companies in the News – February 2012

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

February 14
Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug

Merck to Present at the Leerink Swann 2012 Global Healthcare Conference

Presentation of the Fourth Quarter and Full Year 2011 Report

February 13
Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients with Myelodysplastic Syndromes

February 10
Amicus Therapeutics to Present at Leerink Swann 2012 Global Healthcare Conference

Soligenix Announces Results from its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis

February 9
Advaxis to Present at the 14th Annual BIO CEO & Investor Conference

Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences

Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease

Gilead Sciences to Present at Two Upcoming Investor Conferences

February 8
Immunomedics Announces Second-Quarter Fiscal 2012 Results and Clinical Program Developments

Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012

Amicus Therapeutics to Announce Fourth-Quarter and Full-Year 2011 Financial Results on February 13, 2012

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference

February 7
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar

The NAMES Project Foundation and Merck Launch “Call My Name” National Tour AIDS Panel Making Workshop to Focus Attention on HIV/AIDS Crisis in African American Communities

Amicus Therapeutics Awarded Grant from Muscular Dystrophy Association for Pompe Disease Program

Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

Unigene to Present at the 14th Annual Bio CEO & Investor Conference

February 6
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia

NPS Pharmaceuticals to Present at Upcoming Conferences

Soligenix Demonstrates Positive Proof of Concept with Its Proprietary Vaccine Thermostabilization Technology

Cyclacel to Present at Upcoming Investor Conferences

February 3
SAFE-BioPharma Standard to Be Highlighted at Molecular TriCon

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.

The Medicines Company to Announce Fourth-Quarter and Full-Year 2011 Financial Results on Wednesday, February 22, 2012

February 2
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results

FDA Approves JANUMET XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience

Photocure’s Partner Ipsen Announces 4Q 11 Hexvix Sales in Germany and Italy

Gilead Sciences Announces Fourth-Quarter and Full-Year 2011 Financial Results

February 1
Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award

January 31
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS)

Soligenix Announces 1 for 20 Reverse-Split of Its Common Stock

Immunomedics Awarded Broad Patent for Anti-Cd20 and Anti-Cd22 Combination Therapy

January 26
Celgene to Acquire Avila Therapeutics

Celgene Reports Record Fourth-Quarter and Full-Year 2011 Operating and Financial Results

Temptime and Numedis Collaborate to Bring Proprietary Storage and Transportation Technologies That Advance Corneal Transplant Outcomes

Celator Pharmaceuticals Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia

Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2

Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer

BioReference to Launch Groundbreaking Solid Tumor Genotyping Test through its GenPath Oncology Laboratory

Bristol-Myers Squibb Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of Strategic Transactions and Good Operating Performance

Soligenix Receives $574,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Acsis, Inc. Appoints Paul Allen to Board of Directors

Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data

January 24
Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors

January 23
Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors

Amicus Therapeutics Appoints Bradley L. Campbell as Chief Business Officer

The Medicines Company Settles Angiomax (Bivalirudin) Patent Litigations with App Pharmaceuticals

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, a Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV

January 20
Immunomedics Reports Final Results from Phase IB/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer

Remicade (Infliximab) Receives Positive Opinion From CHMP in Europe for Treatment of Ulcerative Colitis in Pediatric Patients

NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product

January 19
Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients

Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin

EDA Approves Investment in Venture Fund, Announces Incentive Recipients

Three Major IT Trends Will Shape Life Sciences in 2012

January 18
Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine

Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Virtual Collaboration and Training Comes to Life Sciences Organizations

NovaDel Continuing to Explore Strategic Alternatives

First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published

January 17
Antares Pharma Enters Licensing Agreement with Daewoong Pharmaceuticals Co. Ltd. for Oxybutynin Gel 3% in South Korea

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301

Alliance Life Sciences Sponsors CBI Compliance Congress 2012 and Releases White Paper on Proposed Rules for Sunshine Act Implementation